Duke named Zenalux Research Partner
DURHAM, N.C.—Zenalux Biomedical Inc. has announced Duke University as a Zenalux Research Partner. Duke researchers will make use of the Zenascope C49 in a breast tumor margin analysis study, conducting a 200-patient Phase II clinical study to evaluate Zenalux's optical tissue spectroscopy technology as a tool for breast tumor margin assessment. The Zenascope C49 is a multichannel system that uses UV-VIS spectroscopic measurement hardware, proprietary software and patented algorithms to achieve rapid, quantitative and non-destructive analysis of biological tissue characteristics that provide insight into the function and composition of the tissue.
"There is a pressing need to more accurately assess tumor margins during surgery to help minimize repeat surgeries for patients undergoing breast conserving surgery," said Jesko von Windheim, CEO of Zenalux, in a press release.